Endometrial carcinoma

From Libre Pathology
Revision as of 15:29, 10 August 2011 by Michael (talk | contribs) (link)
Jump to navigation Jump to search

Endometrial carcinoma is a common gynecologic malingnancy[1] that often arises from endometrial hyperplasia. The incidence of endometrial carcinoma is increasing, as the proportion of obese individuals is increasing.

An introduction to the endometrium is in the article endometrium.

Clinical

Risk factors

Risk factors for endometrial carcinoma - mnemonic COLD NUT:[2]

  • Cancer Hx (ovarian, breast, colon).
  • Obesity.
  • Late menopause.
  • Diabetes.
  • Nulliparity.
  • Unopposed estrogen (polycystic ovarian syndrome (PCOS), anovulation, hormone replacement therapy (HRT)).
  • Tamoxifen use.
    • Used for breast cancer; the risk is quite small[3] or possibly negligent.[4]

Family history

Several syndromes are seen in association with endometrial cancer:[5]

  • Cowden syndrome (PTEN mutation) - most common.
    • Associated with endometrioid endometrial carcinoma.
  • Lynch syndrome (mutation of a mismatch repair gene - there are several[6]).
    • Associated with non-endometrioid endometrial carcinoma.
    • Autosomal dominant.

Management

"Hysterectomy" is the standard treatment for endometrial carcinoma.

    • In low-grade carcinomas (i.e. low grade endometrioid type), if the woman isn't done with their childbearing, the treatment may be hormones and surveillance biopsies.[7]

Details:

  • Low grade and low stage endometrioid carcinoma: total hysterectomy (includes cervix).
  • Non-endometrioid or high stage endometrioid or high-grade endometrioid: radical hysterectomy (includes cervix, vaginal cuff, parametrial tissue).

Subtypes

They are commonly grouped based on clinicopathologic features:[8]

  1. Type I:
    • Histologic types:
      • Endometrioid (most common).
      • Mucinous.
    • Clinical characteristics: premenopausal, estrogen excess.
  2. Group II:
    • Histologic types:
      • Serous carcinoma.
      • Clear cell carcinoma.
    • Clinical characteristics: postmenopausal, no estrogen excess, poor prognosis.

The most common as a list:

  1. Endometrioid - most common, patient typically is 55-65 years old and obese.
  2. Serous - patients classically older than endometrioid subtype, arise in atrophic endometrium.
  3. Clear cell.

Microscopic (summary)

Features in most common subtypes (in short):

  • Serous:
    • Columnar cells.
    • Cilia.
    • Psammoma bodies.
    • Papillae.
  • Endometrioid:
  • Clear cell.
    • Classically clear cells... but not always.
    • Hobnailing (apical cytoplasm > cytoplasm on basement membrane).

Notes:

Media:Example.ogg

Grading (FIGO)

  • Based on gland formation & adjusted by nuclear pleomorphism:[10][11][12][13]
    • Grade 1: <5% solid component.
    • Grade 2: 5-50% solid component.
    • Grade 3: >50% solid component.

Modifiers/adjustment:

  • High grade nuclei upgrades cancer by one; high grade nuclei = increased size, irregular large nucleoli, irregular chromatin pattern (clumped, coarse).[14]
  • Grading for endometrioid subtype ONLY --papillary serous carcinoma and clear cell carcinomas are grade 3 by definition.

Staging

  • Stage I: confined to uterine body.
    • Ia = endometrium only.
    • Ib = less than half of myometrium.
    • Ic = greater than half of myometrium.
  • Stage II: uterus + cervix.
    • IIa = endocervical glands only.
    • IIb = cervix stroma.
  • Stage III: outside uterus - but inside pelvis.
    • IIIa = serosal or adnexal involvement or peritoneal cytology positive.
    • IIIb = vaginal metstases.
    • IIIc = pelvic or paraaortic nodes.
  • Stage IV: outside true pelvis or in mucosa of bladder or GI tract.
    • IVa = bladder or bowel mucosa.
    • IVb = distant mets (intraabdominal, inguinal nodes).

Ref: [15], [16], [17]

See also

References

  1. Fowler W, Mutch D (September 2008). "Management of endometrial cancer". Womens Health (Lond Engl) 4 (5): 479–89. doi:10.2217/17455057.4.5.479. PMID 19072487.
  2. TN07 GY40
  3. Brown, K. (Sep 2009). "Is tamoxifen a genotoxic carcinogen in women?". Mutagenesis 24 (5): 391-404. doi:10.1093/mutage/gep022. PMID 19505894.
  4. Ashraf, M.; Biswas, J.; Majumdar, S.; Nayak, S.; Alam, N.; Mukherjee, KK.; Gupta, S.. "Tamoxifen use in Indian women--adverse effects revisited.". Asian Pac J Cancer Prev 10 (4): 609-12. PMID 19827879.
  5. Okuda T, Sekizawa A, Purwosunu Y, et al. (2010). "Genetics of endometrial cancers". Obstet Gynecol Int 2010: 984013. doi:10.1155/2010/984013. PMC 2852605. PMID 20396392. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852605/.
  6. Online 'Mendelian Inheritance in Man' (OMIM) 120435
  7. Zivanovic O, Carter J, Kauff ND, Barakat RR (December 2009). "A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer". Gynecol. Oncol. 115 (3): 504–9. doi:10.1016/j.ygyno.2009.08.011. PMID 19758691.
  8. Lim, D.; Oliva, E. (Nov 2010). "Nonendometrioid endometrial carcinomas.". Semin Diagn Pathol 27 (4): 241-60. PMID 21309259.
  9. http://dictionary.reference.com/browse/dyskeratosis
  10. Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease (7th ed.). St. Louis, Mo: Elsevier Saunders. pp. 1087-8. ISBN 0-7216-0187-1.
  11. URL: http://www.pathologyoutlines.com/uterus.html#endometrialcarc.
  12. URL: http://www.emedicine.com/med/topic2832.htm.
  13. Ayhan A, Taskiran C, Yuce K, Kucukali T (January 2003). "The prognostic value of nuclear grading and the revised FIGO grading of endometrial adenocarcinoma". Int. J. Gynecol. Pathol. 22 (1): 71–4. PMID 12496701.
  14. Tadrous, Paul.J. Diagnostic Criteria Handbook in Histopathology: A Surgical Pathology Vade Mecum (1st ed.). Wiley. pp. 240. ISBN 978-0470519035.
  15. Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease (7th ed.). St. Louis, Mo: Elsevier Saunders. pp. 1088. ISBN 0-7216-0187-1.
  16. http://www.emedicine.com/med/topic2832.htm
  17. Staging with groovy graphics (cancerfacts.com)

External links